<code id='EF57475875'></code><style id='EF57475875'></style>

<acronym id='EF57475875'></acronym>

<center id='EF57475875'><center id='EF57475875'><tfoot id='EF57475875'></tfoot></center><abbr id='EF57475875'><dir id='EF57475875'><tfoot id='EF57475875'></tfoot><noframes id='EF57475875'>

<optgroup id='EF57475875'><strike id='EF57475875'><sup id='EF57475875'></sup></strike><code id='EF57475875'></code></optgroup>

<b id='EF57475875'><label id='EF57475875'><select id='EF57475875'><dt id='EF57475875'><span id='EF57475875'></span></dt></select></label></b><u id='EF57475875'></u>

~~<i id='EF57475875'><strike id='EF57475875'><tt id='EF57475875'><pre id='EF57475875'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

leisure time

author：Wikipedia 2025-09-06 03:59:13 Page View：46646

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

advertisement

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Moonlake's readout produced a cash windfall. Risks remain

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

ThisistheonlineeditionofAdam’sBiotechScorecard,anewsubscriber-onlynewsletter.STAT+subscriberscansign

Dobbs anniversary: the lost opportunity of abortion as health care

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

'Essentially witchcraft:' A former naturopath takes on the field

ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears

read more